A structure-based tool to interpret the significance of kinase mutations in clinical next generation sequencing in cancer
Rangarajan, A.; Sviezhentseva, I.; Gunderson, E.; Pikman, Y.; Jacobson, M. P.; Winger, B. A.
Show abstract
IntroductionClinical workflows to analyze variants of unknown significance (VUSs) found in clinical next generation sequencing (NGS) are labor intensive, requiring manual analysis of published data for each variant. There is a strong need for tools and resources that provide a consistent way to analyze variants. With the explosion of clinical NGS data and the concurrent availability of protein structures through the Protein Data Bank and protein models through programs such as AlphaFold, there exists an unprecedented opportunity to use structural information to help standardize NGS analysis with the overall goal of advancing personalized cancer therapy. MethodsUsing the Catalogue of Somatic Mutations in Cancer (COSMIC), the largest curated database of clinical cancer mutations, we mapped thousands of missense mutations in the kinase and juxtamembrane (JM) domains of 48 receptor tyrosine kinases (RTKs) onto structurally aligned kinase structures, then clustered known activating mutations along with VUSs based on proximity in three-dimensional structure. Using cell-based models we illustrate that our resource can be used to identify activating mutations and provide insight into mechanisms of kinase activation and regulation. ResultsWe provide a database of structurally aligned and functionally annotated mutations that can be used as a tool to evaluate kinase VUSs based on their structural alignment with known activating mutations. The tool can be accessed through a user-friendly website in which one can input a kinase mutation of interest, and the system will output a list of structurally analogous mutations in other kinases, as well as their functional annotations. DiscussionWe expect our database to be an important addition to the current tools and resources used to analyze clinical NGS, with important clinical implications to guide recommendations for personalized cancer therapy.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A Genomically and Clinically Annotated Patient Derived Xenograft (PDX) Resource for Preclinical Research in Non-Small Cell Lung Cancer 91%
- Leveraging Allele-Specific Expression for Therapeutic Response Gene Discovery in Glioblastoma. 91%
- PLEKHA4 Promotes Wnt/β-catenin Signaling-Mediated G1/S Transition and Proliferation in Melanoma 91%
Similar papers in this journal
- Constitutive Activation and Oncogenicity Are Mediated by Loss of Helical Structure at the Cytosolic Boundary of the Thrombopoietin Receptor 93%
- Systematic genetic characterization of the human PKR kinase domain highlights its functional malleability to escape a poxvirus substrate mimic 92%
- Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer 92%
Similar papers in this journal
- Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer 95%
- Mutation in Abl kinase with altered drug binding kinetics indicates a novel mechanism of imatinib resistance 94%
- Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2 92%
Similar papers in this journal
- ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells 92%
- Functional anatomy of the full length CXCR4-CXCL12 complex systematically dissected by quantitative model-guided mutagenesis 92%
- Proteome-wide screening for mitogen-activated protein kinase docking motifs and interactors 91%
Similar papers in this journal
- TargetGeneReg 2.0: a comprehensive web-atlas for p53, p63, and cell cycle-dependent gene regulation 91%
- DNA replication during acute MEK inhibition drives acquisition of resistance through amplification of the BRAF oncogene 91%
- Oncogenic ERRB2 signals through the AP-1 transcription factor to control mesenchymal-like properties of oesophageal adenocarcinoma 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.